TTR and cardiomyopathy: A recently published phase 2 trial demonstrated that AG10 treatment was well tolerated in patients with either mutant or wild-type ATTR cardiomyopathy, achieved target plasma concentrations, and demonstrated near-complete stabilization of ATTR.